[Cl:1][C:2]1[CH:3]=[C:4]([C@@H:8]([C@@H:14]2[CH2:19][CH2:18][CH2:17][NH:16][CH2:15]2)[O:9][CH2:10][C:11](=[O:13])[CH3:12])[CH:5]=[CH:6][CH:7]=1.[CH:20]1([CH2:26][C@H:27]([NH:40][C:41](=O)[O:42]C2C=CC([N+]([O-])=O)=CC=2)[CH2:28][N:29]([CH3:39])[C:30]([O:32][CH2:33][CH2:34][Si:35]([CH3:38])([CH3:37])[CH3:36])=[O:31])[CH2:25][CH2:24][CH2:23][CH2:22][CH2:21]1.CCN(C(C)C)C(C)C>C(Cl)Cl>[Cl:1][C:2]1[CH:3]=[C:4]([C@H:8]([O:9][CH2:10][C:11](=[O:13])[CH3:12])[C@@H:14]2[CH2:19][CH2:18][CH2:17][N:16]([C:41]([NH:40][C@@H:27]([CH2:26][CH:20]3[CH2:21][CH2:22][CH2:23][CH2:24][CH2:25]3)[CH2:28][N:29]([CH3:39])[C:30](=[O:31])[O:32][CH2:33][CH2:34][Si:35]([CH3:37])([CH3:38])[CH3:36])=[O:42])[CH2:15]2)[CH:5]=[CH:6][CH:7]=1A mixture of 1-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)propan-2-one, obtained as described above, (S)-4-nitrophenyl 1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)propan-2-ylcarbamate (0.390 g, 0.81 mmol), and DIPEA (2.5 mL) in CH2Cl2 was stirred at rt for 16 h. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 0.0487 g (11.4% in three steps) of 2-(trimethylsilyl)ethyl (S)-2-((R)-3-((R)-(3-chlorophenyl)(2-oxopropoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate. MS ESI +ve m/z 624 (M+H).
読み込み中…